natgillin/translations-raw huggingface dataset:
If the notify party EORI number is not available, the full name and address of the notify party shall be provided.
Kadar številka EORI ni na voljo, se navedeta polno ime in naslov osebe, ki jo je treba obvestiti.
In Annex 37 to Regulation (EEC) No 2454/93, Title II, Section A, Box 8: ‘Consignee’, the following paragraph is inserted after the second paragraph:
V polju 8 („Prejemnik“) dela A naslova II Priloge 37 k Uredbi (EGS) št. 2454/93 se za drugim odstavkom vstavi naslednji odstavek:
‘Where an identification number is required and the declaration includes the particulars for an exit summary declaration as set out in Annex 30a and facilitations are granted in the framework of a third country traders’ partnership programme which is recognised by the Union, that identification number may take the form of a third country unique identification number which has been made available to the Union by the third country concerned. The structure of that third country unique identification number corresponds to the structure as specified in the “Exit summary declarations” part of the data element explanatory note entitled “Consignor”, in Annex 30a.’.
„Kadar se zahteva identifikacijska številka in deklaracija vsebuje podatke za izstopno skupno deklaracijo iz Priloge 30a ter se v okviru programa trgovinskega partnerstva tretje države, ki ga Unija prizna, zagotavljajo olajšave, je lahko ta identifikacijska številka v obliki edinstvene identifikacijske številke tretje države, ki jo je zadevna tretja država sporočila Uniji. Ta edinstvena identifikacijska številka v tretji državi je sestavljena tako, kot je opredeljeno v delu ‚Izstopne skupne deklaracije‘ pojasnila k podatku z naslovom ‚Pošiljatelj‘ v Prilogi 30a.“
In Annex 38 to Regulation (EEC) No 2454/93, Title II, Box 8: ‘Consignee’, the following paragraph is added after the first paragraph:
V polju 8 („Prejemnik“) naslova II Priloge 38 k Uredbi (EGS) št. 2454/93 se za prvim odstavkom vstavi naslednji odstavek:
‘Where an identification number is required and the declaration includes the particulars for an exit summary declaration as set out in Annex 30a, a third country unique identification number which has been made available to the Union by the third country concerned may be used.’.
„Kadar se zahteva identifikacijska številka in deklaracija vsebuje podatke za izstopno skupno deklaracijo iz Priloge 30a, se lahko uporabi edinstvena identifikacijska številka v tretji državi, ki jo je zadevna tretja država sporočila Uniji.“
Where the notify party EORI number or the notify party third country unique identification number is provided, his name and address shall not be provided.’.
Kadar se navede številka EORI osebe, ki jo je treba obvestiti, ali njena edinstvena identifikacijska številka v tretji državi, se ime in naslov te osebe ne navedeta.“
OJ L 152, 16.6.2009, p. 23.’;
UL L 152, 16.6.2009, str. 23.“
OJ L 21, 24.1.2013, p. 19. [3] OJ L 253, 11.10.1993, p. 1.
UL L 21, 24.1.2013, str. 19.
Commission Regulation (EU) No 175/2014
Uredba Komisije (EU) št. 175/2014
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
Uredba (ES) št. 1924/2006 določa tudi, da nosilci živilske dejavnosti vloge za odobritev zdravstvenih trditev lahko vložijo pri pristojnem nacionalnem organu države članice.
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority, for a scientific assessment, as well as to the Commission and the Member States for information.
Nacionalni pristojni organ veljavne vloge posreduje Evropski agenciji za varnost hrane (EFSA: v nadaljnjem besedilu: Agencija) za pripravo znanstvene ocene ter Komisiji in državam članicam v vednost.
The Authority is to deliver an opinion on the health claim concerned.
Agencija poda mnenje o zadevni zdravstveni trditvi.
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and intestinal discomfort (Question No EFSA-Q-2012-00588) [2].
Družba PiLeJe je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 in S. thermophilus LA 104 na črevesno nelagodje (vprašanje št. EFSA-Q-2012-00588) [2].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Improves intestinal comfort’.
Vložnik je med drugim predlagal naslednjo trditev: „Izboljša občutek v črevesju“.
On 12 February 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not been established between the consumption of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and the claimed effect.
Komisija in države članice so 12. februarja 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 in S. thermophilus LA 104 ter navedeno trditvijo ni utemeljena.
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and stool frequency (Question No EFSA-Q-2012-00589) [3].
Družba PiLeJe je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 in S. thermophilus LA 104 na pogostost odvajanja (vprašanje št. EFSA-Q-2012-00589) [3].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Regulates your (intestinal) transit’.
Vložnik je med drugim predlagal naslednjo trditev: „Ureja vaše (črevesno) prehajanje“.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of ♀EFAX™ and reduction of menstrual discomfort (Question No EFSA-Q-2012-00591) [4].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki ♀EFAX™ na zmanjšanje nelagodja med menstruacijo (vprašanje št. EFSA-Q-2012-00591) [4].
The claim proposed by the applicant was worded, inter alia, as follows: ‘♀EFAX™ contributes to maintain a normal menstruation cycle’.
Vložnik je med drugim predlagal naslednjo trditev: „♀EFAX™ prispeva k ohranjanju normalnega menstrualnega ciklusa“.
On 12 February 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of ♀EFAX™ and the claimed effect.
Komisija in države članice so 12. februarja 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem ♀EFAX™ in navedeno trditvijo ni utemeljena.
Following an application from Kemin Foods LC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Slendesta® Potato Extract and reduction of body weight (Question No EFSA-Q-2012-00704) [5].
Družba Kemin Foods LC je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki krompirjevega ekstrakta Slendesta® na zmanjšanje telesne teže (vprašanje št. EFSA-Q-2012-00704) [5].
The claim proposed by the applicant was worded as follows: ‘Slendesta® contributes to the reduction of body weight in overweight individuals’.
Vložnik je predlagal naslednjo trditev: „Slendesta® prispeva k zmanjšanju telesne teže pri posameznikih s prekomerno telesno težo“.
On 12 February 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Slendesta® Potato Extract and the claimed effect.
Komisija in države članice so 12. februarja 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem krompirjevega ekstrakta Slendesta® in navedeno trditvijo ni utemeljena.
Following an application from Zambon B.V., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Monurelle® and reduction of bacterial colonisation of the urinary tract (Question No EFSA-Q-2012-00737) [6].
Družba Zambon B.V. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Monurelle® na zmanjšanje bakterijske kolonizacije v urinarnem traktu (vprašanje št. EFSA-Q-2012-00737) [6].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Proanthocyanidins from Monurelle® may help to support defence against bacterial pathogens in the lower urinary tract’.
Vložnik je med drugim predlagal naslednjo trditev: „Proantocianidini iz Monurelle® lahko pomagajo pri razvoju zaščite proti bakterijskim patogenom v spodnjem urinarnem traktu“.
On 12 February 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Monurelle® and the claimed effect.
Komisija in države članice so 12. februarja 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Monurelle® in navedeno trditvijo ni utemeljena.
Following an application from S.A. Vichy Catalan, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Vichy Catalan carbonated natural mineral water and reduction of post-prandial lipaemic response (Question No EFSA-Q-2012-00872) [7].
Družba S.A. Vichy Catalan je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki naravne mineralne vode z dodanim ogljikovim dioksidom Vichy Catalan na zmanjšanje lipemičnega odziva po obroku (vprašanje št. EFSA-Q-2012-00872) [7].
The claim proposed by the applicant was worded as follows: ‘Vichy Catalan, a bicarbonated natural mineral water rich in mineral salts, contributes to reduce blood triglycerides rise during digestion’.
Vložnik je predlagal naslednjo trditev: „Naravna mineralna voda z dodanim dvojnim ogljikovim dioksidom Vichy Catalan, bogata z mineralnimi solmi, prispeva k zmanjšanju dviga trigliceridov v krvi med presnovo“.
On 12 February 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Vichy Catalan carbonated natural mineral water and the claimed effect.
Komisija in države članice so 12. februarja 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem naravne mineralne vode z dodanim ogljikovim dioksidom Vichy Catalan in navedeno trditvijo ni utemeljena.
The health claim related to Slendesta® Potato Extract is a health claim as referred to in point (c) of Article 13(1) of Regulation (EC) No 1924/2006 and is therefore subject to the transitional period laid down in Article 28(6) of that Regulation.
Zdravstvena trditev v zvezi s krompirjevim ekstraktom Slendesta® je zdravstvena trditev iz točke (c) člena 13(1) Uredbe (ES) št. 1924/2006, zato zanjo velja prehodno obdobje iz člena 28(6) navedene uredbe.
However, as the application was not made before 19 January 2008, the requirement provided for in point (b) of Article 28(6) of that Regulation is not fulfilled, and therefore this claim may not benefit from the transitional period provided for in that Article.
Ker pa vloga ni bila vložena pred 19. januarjem 2008, zahteva iz točke (b) člena 28(6) navedene uredbe ni izpolnjena, zato se prehodno obdobje iz navedenega člena za to trditev ne more uporabiti.
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Zdravstvena trditev po členu 13(5), ki je utemeljena na novih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
A combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104
Kombinacija B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 in S. thermophilus LA 104
Improves intestinal comfort
Izboljša občutek v črevesju.
Regulates your (intestinal) transit
Ureja vaše (črevesno) prehajanje.
♀EFAX™ contributes to maintain a normal menstruation cycle
♀EFAX™ prispeva k ohranjanju normalnega menstrualnega ciklusa.
Slendesta® Potato Extract
Krompirjev ekstrakt Slendesta®
Slendesta® contributes to the reduction of body weight in overweight individuals
Slendesta® prispeva k zmanjšanju telesne teže pri posameznikih s prekomerno telesno težo.
Proanthocyanidins from Monurelle® may help to support defence against bacterial pathogens in the lower urinary tract
Proantocianidini iz Monurelle® lahko pomagajo pri razvoju zaščite proti bakterijskim patogenom v spodnjem urinarnem traktu.
Vichy Catalan carbonated natural mineral water
Naravna mineralna voda z dodanim ogljikovim dioksidom Vichy Catalan
Vichy Catalan, a bicarbonated natural mineral water rich in mineral salts, contributes to reduce blood triglycerides rise during digestion
Naravna mineralna voda z dodanim dvojnim ogljikovim dioksidom Vichy Catalan, bogata z mineralnimi solmi, prispeva k zmanjšanju dviga trigliceridov v krvi med presnovo.
The list of permitted health claims has been established by Commission Regulation (EU) No 432/2012 [8] and is applicable since 14 December 2012.
Seznam dovoljenih zdravstvenih trditev je bil določen z Uredbo Komisije (EU) št. 432/2012 [8] in se uporablja od 14. decembra 2012.
As regards claims referred to in Article 13(5) of Regulation (EC) No 1924/2006 for which the evaluation by the Authority or consideration by the Commission has not been completed by 14 December 2012 and which by virtue of this Regulation are not included in the list of permitted health claims, it is appropriate to provide for a transitional period during which they may still be used, in order to allow both food business operators and the competent national authorities to adapt to the prohibition of such claims.
Za trditve iz člena 13(5) Uredbe (ES) št. 1924/2006, za katere ocena Agencije ali presoja Komisije ni bila zaključena do 14. decembra 2012 in katere na podlagi te uredbe niso vključene v seznam dovoljenih zdravstvenih trditev, je primerno določiti prehodno obdobje, v katerem se še vedno lahko uporabljajo, da se nosilci živilske dejavnosti in nacionalni pristojni organi lahko prilagodijo na prepoved takih trditev.
Commission Regulation (EU) No 176/2014
Uredba Komisije (EU) št. 176/2014
amending Regulation (EU) No 1031/2010 in particular to determine the volumes of greenhouse gas emission allowances to be auctioned in 2013-20
o spremembi Uredbe (EU) št. 1031/2010 zlasti zaradi določitve količine pravic do emisije toplogrednih plinov, ki se bodo prodajale na dražbi med letoma 2013–2020
Directive 2003/87/EC provides for determining the timing, administration and other aspects of auctioning to ensure that it is conducted in an open, transparent, harmonised and non-discriminatory manner.
Direktiva 2003/87/ES predvideva določitev časovnega načrta, upravljanja in drugih vidikov dražbe, da se zagotovi odprta, pregledna, usklajena in nediskriminatorna izvedba dražbe.
It also provides for the Commission to monitor the functioning of the European carbon market.
Določa tudi, da Komisija spremlja delovanje evropskega trga ogljika.
Commission Regulation (EU) No 1031/2010 [2] provides the volumes of allowances to be auctioned each year, after deducting the allocation given free of charge from the Union-wide quantity of allowances issued in the same year.
Uredba Komisije (EU) št. 1031/2010 [2] določa količine pravic, ki se vsako leto prodajo na dražbi, po odštetju brezplačne dodelitve od količine pravic za celotno Unijo, izdanih istega leta.
A deviation from this time profile has also been decided in Commission Regulation (EU) No 1210/2011 [3] to determine a volume of allowances to be auctioned early, prior to 2013, with corresponding reductions in the 2013 and 2014 auction volumes, with the foremost objective to ensure a smooth transition from the second to the third trading period, taking due account of the hedging needs for compliance in the early years of the third trading period.
V Uredbi Komisije (EU) št. 1210/2011 [3] je bilo določeno tudi odstopanje od tega časovnega razporeda, da se določi količina pravic, ki se bodo na dražbi prodajale zgodaj, pred letom 2013, z ustreznimi zmanjšanji v količinah za dražbo v letih 2013 in 2014 in z glavnim ciljem, da se zagotovi gladek prehod iz drugega na tretje trgovalno obdobje ob upoštevanju potreb po skladnosti na področju varovanja pred tveganjem v začetnih letih tretjega trgovalnega obdobja.
These annual volumes were decided based on the factors determining supply of and demand for allowances at the time of the assessment and assumption of an ongoing economic recovery.
Te letne količine so bile določene na podlagi dejavnikov, ki določajo ponudbo in povpraševanje po pravicah v času ocene in predpostavko, da bo v tem času potekala oživitev gospodarstva.
Account should be taken of exceptional changes in drivers determining the balance between the demand for and supply of allowances, notably the renewed economic slowdown, as well as temporary elements directly related to the transition to phase 3, including increasing unused volume of allowances valid for the second trading period for compliance in the said period, increasing volumes of certified emission reductions and emission reduction units from emission reduction projects under the Clean Development Mechanism or under Joint Implementation provisions for surrendering by operators covered by the scheme, the monetisation of allowances from the new entrants reserve for the third trading period for support of demonstration projects of carbon capture and sequestration and innovative renewable energy technologies (‘NER300’) pursuant to Commission Decision 2010/670/EU [4] and release of allowances not needed in the new entrants reserves for the second trading period.
Upoštevati je treba izjemne spremembe v dejavnikih, ki določajo ravnovesje med povpraševanjem in ponudbo po pravicah, zlasti ponovno upočasnitev gospodarske rasti in začasne elemente, ki so neposredno povezani s prehodom na fazo 3, vključno s povečanjem neuporabljene količine pravic, veljavnih za drugo trgovalno obdobje, za skladnost v navedenem obdobju, povečane količine potrjenih zmanjšanj emisij in enot zmanjšanj emisij iz projektov zmanjšanja emisij v okviru Mehanizma čistega razvoja ali določb skupnega izvajanja za predajo s strani upravljavcev iz sistema, monetizacijo pravic iz rezerve za nove udeležence za tretje trgovalno obdobje za podporo demonstracijskih projektov zajemanja in shranjevanja ogljika ter inovativne tehnologije obnovljive energije (NER300) v skladu s Sklepom Komisije 2010/670/EU [4] in izdajo pravic, ki niso potrebne v rezervah za nove udeležence za drugo trgovalno obdobje.
Although all these factors are subject to different degrees of uncertainty, it is important to determine appropriate corrections to the annual volumes to be auctioned in 2014-20 in a timely manner.
Čeprav so stopnje negotovosti teh dejavnikov različne, je pomembno, da se pravočasno določi ustrezne popravke letne količine pravic, ki se bodo v letih 2014–2020 prodajale na dražbah.
Reducing the risk of carbon leakage (an increase in greenhouse gas emissions in third countries where industry would not be subject to comparable carbon constraints) and avoiding putting certain energy-intensive sectors and subsectors in the EU which are subject to international competition at an economic disadvantage, is an important consideration in EU climate policy.
Zmanjševanje tveganja selitve virov CO2 (povečanja emisij toplogrednih plinov v tretjih državah, kjer industrija ne bi bila izpostavljena enakim omejitvam emisij CO2) in preprečevanje gospodarske škode za nekatere energetsko intenzivne sektorje in podsektorje v EU, ki so izpostavljeni mednarodni konkurenci, sta pomembna vidika v podnebni politiki EU.
Accordingly, the Commission analysed the impacts on the competitive situation of energy-intensive industries to be expected from the review of the auction time profile [5], using assumptions that remain valid as of January 2014.
Zato je Komisija analizirala vplive na konkurenčni položaj energetsko intenzivnih industrijskih sektorjev, ki jih je mogoče pričakovati glede na pregled časovnega profila dražb [5], pri čemer se uporabljajo predpostavke, ki ostajajo veljavne od januarja 2014.
The impact assessment noted that Directive 2003/87/EC has put in place measures, including the continued free allocation of emission allowances and the adoption of a list of industries deemed to be at risk of carbon leakage, to address the risk of carbon leakage for energy-intensive industrial sectors.
V oceni učinka je bilo ugotovljeno, da je Direktiva 2003/87/ES uvedla ukrepe, vključno z nadaljnjim brezplačnim dodeljevanjem pravic do emisije in sprejetjem seznama industrijskih sektorjev, za katere velja, da so izpostavljeni tveganju selitve virov CO2, da se prepreči tveganje selitve virov CO2 za energetsko intenzivne industrijske sektorje.
As the volume to be auctioned in each year of the period 2014-16 is reduced, the thresholds for the auction volume per individual auctions on an auction platform appointed by a Member State not participating in the joint action should be reduced accordingly.
Ker je količina pravic, ki se bodo vsako leto obdobja 2014–2016 prodajale na dražbi, zmanjšana, bi bilo treba ustrezno zmanjšati tudi prage glede količine prodanih pravic, veljavne za posamezne dražbe, izvedene znotraj dražbenega sistema, ki ga imenuje država članica, ki v skupnem ukrepu ne sodeluje.
In order to apply to auctions taking place from 2014 onwards, and to ensure orderly functioning of the carbon market and predictable auctions, this Regulation should enter into force without delay.
Da bi se lahko uporabljala za dražbe, ki bodo potekale od leta 2014 dalje, in da se zagotovijo urejeno delovanje trga ogljika in napovedljive dražbe, mora ta uredba začeti veljati nemudoma.
after the second subparagraph of Article 10(2), the following subparagraphs are added:
za drugim pododstavkom člena 10(2) se dodajo naslednji pododstavki:
‘The volume of allowances to be auctioned in a given year determined pursuant to the first or second subparagraphs of this paragraph in 2014-16 shall be reduced by the quantity of allowances for the respective year set out in the second column of the table in Annex IV to this Regulation.
„Količina pravic, ki se bodo prodajale na dražbi v določenem letu v obdobju 2014–2016, določena v skladu s prvim ali drugim pododstavkom tega odstavka, se zmanjša za količino pravic za zadevno leto, določeno v drugem stolpcu preglednice v Prilogi IV k tej uredbi.